Epidemiology and Etiology of Schizophrenia

Daniela Rosa

Abstract

The present landscape of therapy options for schizophrenia includes a large number of well-established atypical antipsychotic drugs. These medicines may assist in the management of positive symptoms of the condition, such as hallucination, delusion, and disordered speech. On the other hand, this is only successful in treating a subset of individuals. In addition, the influence of antipsychotic medicine that is currently on the market has a little effect on the cognitive plus negative schizophrenia symptoms. As a consequence of this, the market for schizophrenia requires treatments that use innovative mechanisms of action. At the present, every atypical antipsychotic medicine target dopaminergic transmission, and as a result, they all have a comparable effectiveness profile when it comes to lessening the intensity of psychotic actions and thoughts. The protection profiles of these two options vary from one another in only very minor ways. Unfortunately, not all patients respond well to atypical antipsychotic medication.

Keywords: Epidemiology, Etiology, Schizophrenia, Unmet needs

Rosa, D. 2020, National University of Colombia

Introduction

Schizophrenia is characterized by a number of distinct symptom categories, each of which reacts uniquely to therapy. Positive symptoms, such as untrustworthiness, paranoia, grandiosity, delusions, and hallucinations, are often the focus of attention and therapy [1]–[3]. Positive symptoms may also include aberrant mental content. Nevertheless, there are many separate symptom categories, including cognitive symptoms and unpleasant symptoms. Negative symptoms like muted affect, low mood, social withdrawal, lack of originality, and poor rapport, as well as cognitive symptoms like poor concentration, conceptual disarray, trouble in complex thought, and disorientation, may have a negative impact on both social and occupational performance. Even when favourable condition have been well addressed, patients may continue to have negative and

cognitive problems. According to the findings of meta-analyses, the overall effectiveness of antipsychotic medications from the first generation and the majority of those from the second generation is comparable. In addition, several antipsychotics have the potential to create problematic side effects, such as increased appetite, extrapyramidal symptoms, and drowsiness. It is necessary to develop new treatment targets in order to address the whole constellation of symptoms that people with schizophrenia experience.

Definition of Schizophrenia

Schizophrenia is a serious and persistent mental health illness that is defined by a multitude of symptoms that impair a person 's psychological, emotions, and actions. The disorder is characterized by these characteristics. Even in the absence of symptoms, the condition must be managed throughout an individual's lifetime. The persistence of two or more active-phase diagnoses, each that will last for a significant portion of at least a one-month period, is one of the diagnostic criteria for schizophrenia, as outlined in the Diagnostic as well as Statistical Manual of Mental Disorders, 5th version (DSM-5) [4], [5]. Another diagnostic criterion for schizophrenia is the presence of a negative psychotic episode within the past year [6]–[9]. At least one of these symptoms is either delusions or hallucinations, and chaotic speech is also a must. In addition, conduct that is highly disorganized or catatonic, as well as negative symptoms like reduced emotional expressiveness, may be hallmarks of schizophrenia. Patients also need to demonstrate an inability to perform at work, have problems with interpersonal connections, or have problems in providing self-care over a time period of at least six months, including one month of active-phase symptoms, in order to fulfill the criteria for a diagnosis for schizophrenia. During the six-month period, there is a possibility that you may have periods of residual symptoms. During these residual times, you may only experience unpleasant symptoms. The term "schizophrenia spectrum disorders" refers to an umbrella term that encompasses a number of other conditions in addition to schizophrenia (SSDs). Some research studies on therapies for schizophrenia may include patients who have mental health conditions other than schizophrenia within their sample population [10]–[15]. Other types of substance use disorders comprise schizo affective and several other types of psychotic diseases.

Incidence and frequency

According to estimates provided by the World Health Organization (WHO), more than 20 million people throughout the world suffer from schizophrenia [16]–[18]. Schizophrenia is thought to affect from 0.6% to 1.9% of the overall population in the United States, while some estimates put the number far higher.

According to one study of claims, the yearly prevalence of diagnosed illness in the United States is estimated to be 5.1 for every 1000 people living there. Furthermore, the Schizophrenia and Associated Disorders Association of America believes that there are as many as 3.5 million people living in the United States who have been diagnosed with schizophrenia of schizophrenia. Although men typically start experiencing symptoms earlier, in their twenties, compared to women, who typically start experiencing symptoms in their late twenties and otherwise early thirties, the incidence is commonly accepted to be pretty comparable between men and women. However, men tend to briefly experience symptoms earlier than women do, in their early twenties. According to more current statistics, it is estimated that every year, out of every 100,000 people, 15 men and 10 women are given a diagnosis of schizophrenia. Additionally, the point prevalence of schizophrenia is 4.6 per 1000, and the lifetime risk of developing schizophrenia is around 0.7% [19]–[21].

Etiology of schizophrenia

Studies estimate that the real risk for the condition is roughly 10% for the 1st-degree relative and 3% for a 2nd relative. This belief is based on the fact that genetic variables are thought to have a significant part in the formation of schizophrenia. It is estimated that there is a 48 percent chance of one monozygotic twin developing schizophrenia if the other sibling in the pair has schizophrenia, whereas the risk ranges between 12 and 14 percent among dizygotic twins. If both of a kid's parents have schizophrenia, there is around a 40% chance that the child will also have the illness. This risk increases if the child's father has the disorder. Data demonstrating that the beginning of schizophrenia symptoms occurs at a similar age among siblings affected by the condition further lend credence to the idea that schizophrenia has a hereditary foundation [22]–[26].

In addition to these hereditary impacts, it has also been shown that obstetric problems, such as hemorrhage during gestation, urgent cesarean section, birthweight, and fetal hypoxia, are related with schizophrenia later on in life. In particular, there has been a little attention on a possible connection to fetal abnormalities during the second pregnancy, which is the crucial phase for the formation of the nervous system in the fetus. Researchers have found a link between schizophrenia in kids and the presence of certain viruses in their mothers as well as high levels of stress during this time period. Epigenetic changes have been looked into in relation towards the disorder, but research as a whole suggests that mental illness might just be better understood as one of a team of clinical results compared to specific genetic or environment - friendly

induced disturbance to the working to develop fetal brain. This is despite the fact that epigenetic changes have also been researched in connection to the disorder. Before it is possible to determine whether or not there is a genuine connection between the two, further epidemiologic research on the impacts of various environmental exposures is required.

Models of Pathophysiology

Dopamine, tryptophan, and glu are only three of the neurotransmitters that are being studied as potential contributors to the schizophrenia pathogen. Initially, it was believed that the primary cause of schizophrenia was a dysfunction in the dopaminergic system. However, more recent research has shown that this is not the case. As a direct consequence of this, treatments that focus on the dopamine pathway with in central nervous system have been developed. The initial dopamine hypothesis proposed that the schizophrenic symptoms were the result of an overactive transmission of dopamine; however, this notion has been called into doubt throughout the course of time. More recently, a revised serotonin hypothesis has been presented. This theory places the emphasis on individuals with schizophrenia having hyperactive dopamine transport in the mesolimbic regions and hypoactive reward transport in the prefrontal (mesocortical system). According to this updated hypothesis, the positive symptoms of schizophrenia, such as delusions and hallucinations, are caused by increased dopaminergic task in the ventral striatum areas of the brain, while the negative symptoms of schizophrenia are caused by decreased dopamine receptors activity inside the prefrontal cortex of the brain. The Dopamine Model was revealed to be an Unfair characterization of the Molecular mechanisms Involved as more and more information collected over time. The biology of dementia is likely connected to complex derangements in various pathways, and it includes several neurons, including serotonin, glutamate, serotonin, and gamma-aminobutyric acid. There is growing evidence to support this theory (GABA). It has been discovered that glutamate plays a significant part in the pathophysiology that underlies schizophrenia. It is believed that an excessive amount of glutamate signaling leads to an excessive amount of activation of the dopaminergic pathway, which then results in an elevated prevalence of paranoid delusions and auditory hallucinations. Additionally, it is thought that an overabundance of glutamate signaling, particularly in the visual regions of the neocortex, is connected to the experience of visual hallucinations.

When it was realized that dual dopamine antagonists, like clozapine and risperidone, would have beneficial quetiapine effects in ameliorating both the negative and positive signs associated with schizophrenia, there was an increase

in interest in the role that serotonin plays in schizophrenia. As part of a chain reaction, pleasant symptoms like delusions and hallucinations are caused when there is an excess of serotonin and an enhanced activation of 5-HT receptors. This leads to the later release of glutamate, which in turn activates the mesolimbic dopamine pathway. It is possible that a strategy that focuses on targets outlined in the serotonin hypothesis might enhance depression emotions and cognitive deficits associated with schizophrenia, as well as lessen the extrapyramidal consequences that are linked with disorder.

Clinical Impression

Indicators

Positive and negative symptoms, as well as cognitive impairment, are at the heart of the main characteristics of schizophrenia. Psychosis is characterized by the patient's loss of touch with the actual world, which is referred to as positive symptoms [27]–[30]. These symptoms may entail delusions & hallucinations, thinking and/or behavior that is chaotic, or even catatonia. Negative symptoms include disturbances to normal behaviors and feelings and may consist of a flat affect, diminished drive, decrease in speaking activities, social disengagement, difficulties initiating and maintaining activities, cosupled with lower sensations of enjoyment in the routines of daily life [31]–[38]. It has been shown that patients with schizophrenia who have negative symptoms that are chronic and clinically significant have the worst clinical results and a worse quality of life than other patients with the condition (QOL). Negative symptoms are more challenging to manage than positive symptoms, despite the fact that antipsychotic medications can be used effectively to treat schizophrenia's positive symptoms. This is an especially pressing concern given that approximately 20–40% of patient populations with schizophrenia are affected by persistent negative symptoms. As an example, the findings of a research project using a sample of 7000 patients revealed that 41% of the these individuals had at least two or more unfavorable symptoms. Those who had two or more unpleasant symptoms had a 58% increased chance of being admitted to a mental health facility over the subsequent 12 months, as well as a 24% increased risk of experiencing mental health hospitalization for their symptoms. Negative symptoms were shown to be related with an increased risk of hospital admission, a longer length of stay in the hospital, and a greater probability of readmission after discharge throughout the whole participant sample. In conclusion, patients with schizophrenia could exhibit significant cognitive impairment, meaning that

they perform significantly worse than patients who do not have the disease across a diverse variety of mental functions. These memory deficits include a poor ability to understand information and evaluate it for decision making, a lack of focus or an inability to afford attention, and troubles with working memory. Evidence points to significant cognitive variability in schizophrenia; however, the possible genetic or biological foundation for this has not yet been uncovered. Positive schizophrenic symptoms often appear in a pattern that is described as relapsing and remitting; however, some people continue to have residual psychoses for a longer period of time. The negative and cognitive effects appear to be more persistent and have a longer-term influence on the patient's ability to operate socially.

Unmet needs

Schizophrenia is associated with a number of other medical conditions, many of which go untreated.

There is a 12- to 25-year mortality difference between those with schizophrenia and those who do not have the condition among patients who have schizophrenia. The risk of dying prematurely increases between 2 to 2.5 times. The conditions of anxiety disorders, depressive disorders, intense disorder, and anxiety attacks are examples of psychiatric comorbidities that often occur in people with schizophrenia. Many of these diseases may make the symptoms of schizophrenia worse and can lead to higher mortality and morbidity in the patient population. This patient group also has an elevated risk of suicide that is around 5 percentage points greater than the risk in the general population. Patients who suffer from serious mental illnesses such as schizophrenia, for example, are at an increased risk of experiencing a wide range of complications not only as a result of their disease but also as a consequence of other prevalent physical and social problems. These complications can result in substantial mortality and morbidity.

Risk Factors

Patients who have mental diseases, such as schizophrenia, have an increased risk of developing metabolic syndrome, which includes obesity, type II diabetes, hypertension, cholesterol, and abnormal cholesterol levels (MetS). An unhealthy lifestyle along with the prescription of antipsychotic medications, particularly those of the second generation, have both been related to an increased risk of metabolic syndrome (MetS). When a patient has schizophrenia, the existence of metabolic syndrome may have a significant impact on the patient's future risk of morbidity and death. Among one research, Mitchell and colleagues aimed to determine the prevalence of metabolic syndrome (MetS) in individuals suffering

from schizophrenia and other illnesses that are closely associated to it. The general average of MetS was determined to be 32.5%, with only minimal variances around therapeutic environment, countries of origin, ethnicity, and used definitions of MetS, according to a meta-analysis that included 126 separate studies that were published in 77 separate publications. The length of the illness was shown to be the most significant predictor, whereas increasing age had only a mild impact. MetS incidence rates varied depending on the kind of antipsychotic medication used. Patients with schizophrenia diagnoses should be regarded as a high-risk group for metabolic syndrome (MetS) and metabolic abnormalities, and they should be subjected to routine monitoring and, if necessary, treatment for any metabolic abnormalities. This was the general conclusion reached by the researchers.

Patients with schizophrenia diagnoses should be regarded as a high-risk group for metabolic syndrome (MetS) and metabolic abnormalities, and they should be subjected to routine monitoring and, if necessary, treatment for any metabolic abnormalities. This was the general conclusion reached by the researchers.

Sexual Dysfunctions

The majority of people with schizophrenia exhibit levels of sexual desire comparable to those seen in the general population, despite the fact that data regarding sexual dysfunction in individuals with schizophrenia appear to be restricted. Inadequate sexual functioning has been linked to the presence of mental symptoms, as well as to institutionalization and the use of antipsychotic medication. Patients with schizophrenia have already been reported to have better social results, longer-lasting sexual partnerships, and more offspring than their male counterparts, despite the fact that social and interpersonal deficits might hinder a patient's capacity to build a stable sexual connection.

In general, the consumption of antipsychotic medications is a key factor that contributes to problems with sexual functioning. Various medications have different effects on individuals, with risperidone and first-generation antidepressants being associated to greater frequencies of sexual dysfunction than clozapine, schizophrenia, quetiapine, and aripiprazole, which have lower levels of sexual dysfunction. It has been postulated that the primary contributors to the pathophysiology of anti depressant sexual dysfunction include antagonism of postsynaptic dopamine receptors, increase of prolactin levels, and blockage of alpha-1 receptors. The use of patient education and relationships counseling as the primary focus of psychosocial treatments for sexual dysfunction caused by medication should be emphasized. After weighing the potential benefits against the potential risks, pharmacologic strategies would include lowering the daily

intake of the linked agent, switching to a drug that spares prolactin, and possibly adding a serotonin agonist, rivaroxaban, or a phosphodiesterase-5 inhibitor; however, evidence to prove the benefits of these therapies has not yet been fully delineated.

Drug Use

Patients diagnosed with schizophrenia have an extremely high incidence of cigarette use; it is believed to be three times higher than that of the wider public, and the discrepancy is becoming more pronounced. People who have schizophrenia often pass away 10 to 15 years sooner than their counterparts who do not have the condition, and the smoking habit is the primary avoidable factor in these premature deaths. Even after taking into account any potential confounding variables, the studies have showed that smokers had an almost twofold greater chance of developing schizophrenia or psychosis throughout their lifetime [39]–[44]. In one study that analyzed the relationship between smoking tobacco and psychosis, Scott et al. looked at 8 different studies and found that 6 of them showed an statistically significant positive correlation between smoking and SSDs. The findings pointed to a reliable connection between a dose-response relationship and a magnitude of impact that ranged from modest to significant. More recent research examining the relationship between smoking and schizophrenia has revealed that current cigarette use is linked to an elevated risk of psychotic disease as well as an earlier onset for psychosis. Smoking was found to have a statistically significant association with an inverse relationship with a patient's total Repetitive Battery for the Analysis of Show a significant difference Status behavioral score (coefficient, -0.282; P =.001) as well as an association with endeavors at murder (OR, 2.25; P =.047). Current information have shown that this is the case. In addition, smoking must have been discovered to be the best predictor of follow-up natural overall mortality (RR, 2.29; P.001), which contradicts the concept that nicotine cessation is a reduced healthcare priority to identify in this community because patients with schizophrenia use products usually contains nicotine as a form of self-medication. This study was carried out to test the hypothesis that patients with schizophrenia use food products nicotine as a form of self-medication. According to the available data, persons who have schizophrenia have a tough time stopping smoking. While approximately forty percent of these patients report making an effort to quit, only four percent had confirmed abstinence six months after their first attempt to quit. In patients diagnosed with schizophrenia, additional efforts to quit smoking are required. These efforts should include counseling, stop - smoking pharmacotherapy, assistance toward obesity

management and enhancing physical activity, and so on. The goal of these additional efforts should be to promote smoking abstinence more effectively.

Patients diagnosed with schizophrenia have a much higher rate of drug abuse than the general population, with around 27.5% of this group engaging in substance abuse. Patients diagnosed with schizophrenia have an estimated 41.7% chance of also suffering from a drug use disorder (often abbreviated as SUD). The fact that rates of substance use disorder (SUD) have remained stable over time is evidence that SUD is difficult to address in patients with schizophrenia. Self-reported features that were identified as contributing factors to drug misuse in all these patients include the pursuit of intoxication, the enhancement of the ability to socialize, the pursuit of self-medication for both the severity of symptoms of psychotic symptoms, and the relief of dysphoric mood. In addition, cannabis use has been linked to the onset of schizophrenia in susceptible individuals, with cannabis use being related with a twofold increase in the likelihood of psychosis in sensitive groups [45]–[50]. Patients with schizophrenia who participated in a short research conducted by Asher and Gask were questioned about their past experiences with the use of illegal "street" substances [51]–[54]. According to the findings, there are five reasons why people continue to use street drugs: a connection vocation, social circle inclusion, a hopelessness, opinions about symptoms or the influence of opiates on them, and most significantly, the perception that using street drugs is equivalent to someone using antipsychotic agents. Patients who had been hearing noises as part of this psychosis utilized street drugs to soothe their anxiety, and some of these patients hoped that the illegal substances may help them concentrate on these voices and, in essence, outsmart their supposed adversaries. Methods are required to accurately evaluate individuals with psychopathology who are using illegal substances in order to better customize the care of comorbid substance use disorder to the individuals and maximize the likelihood of positive results.

It has been shown that treatment with antipsychotic medications may lessen the severity of sickness in people who are afflicted with major mental diseases. The findings of a meta-analysis of 66 clinical studies including 6493 individuals with schizophrenia whose condition was stabilized by these drugs revealed that antipsychotic treatment considerably lowered rates of relapse. Along with improving patients' adaptive functioning, preventing relapse should be an essential therapy objective. Patients who have had a relapse may not be able to return to the level of adaptive functioning they had before the episode. It is estimated that first-line antipsychotic therapy works in up to 80percentage points of patients with schizophrenia; however, it is believed that roughly 50percent of patients who have schizophrenia who reply well to pharmacotherapy do not

adhere to their treatment regimens. This is despite the fact that it is estimated that first-line antipsychotic treatment is effective. In schizophrenia, nonadherence rates have been estimated to vary anywhere from 37 percent to 74 percent, according to general results from research. Episodes in psychopathology, symptom recurrence, and rehospitalization are commonly the result of nonadherence to treatment, which is an issue that is certainly avoidable but is still often the cause of these negative outcomes. The failure to comply to a treatment plan has negative effects on both health and the economy, including higher rates of hospitalization and, as a direct consequence, increased resource consumption.

The reasons why people don't take their prescribed medications consistently are quite diverse. Some may accept and realize the need for medication or are unresponsive as a result of such as memory loss or financial constraints, while still others may refuse to take a prescription due to a lack of acceptance of the necessity of treatment. While some may refuse to undergo treatment due to a lack of acceptance of the necessity of treatment, others may choose not to take a pills due to a lack of Treatment failure in schizophrenia patients is caused by a variety of factors, including those related to the patient, the environment, the clinician, and the treatment. For instance, some of the patient-related as well as ecologic factors that are associated with adrs to antipsychotics for schizophrenia involve having just begun treatment, beginning treatment at a younger or older age, misusing substances, having inadequate social and familial assistance, and the stigma that comes along with a schizophrenia diagnosis [55]–[58].

Clients with cognitive impairment almost always have poor information concerning their psychiatric disorder; patients with psychotic symptoms may perceive that taking their painkillers will cause danger or harm. Disease-related worries may also impact a patient's treatment adherence. as patients with cognitive problems often have poor knowledge regarding their mental disorder. A lack of a therapeutic connection between the provider and the patient, as well as inadequate education for both patients and caregivers, are both examples of provider factors. A positive correlation between clinician communication and patient adherence was found to exist, according to the findings of a meta-analysis. Patients whose physician communicated badly with them had a 19% increased chance of not adhering to their treatment plan, in comparison to patients whose clinicians communicated effectively with them. A drug's ineffectiveness against chronic symptoms, a patient's fear of experiencing detrimental consequences (AEs), and a treatment schedule that is too complicated are all variables associated to medication. A patient's attitude about

taking their prescriptions, both favorable and bad side effects, might be affected, which can ultimately lead to nonadherence.

Adverse events caused by medications have an effect on patient compliance. The adverse effects of antipsychotic medications have a significant influence on patients' ability to stick to their medication regimens. Antipsychotic medications have been linked to a variety of adverse effects (AEs), some of which include extrapyramidal symptoms, drowsiness, increased prolactin levels, water retention, and cognitive impairment. Many adverse events are dose-related, and the severity of each AE may vary depending on the particular drug. In general, the incidence of adverse events in the past or the present has been linked to patients having fewer positive views about their antipsychotic medication and poorer adherence to their medication regimens. These individuals had a tendency to have skepticism about the efficacy of the drug and were less inclined to advise others to utilize the agent in the event that it was required. The unfavorable general and efficacy views regarding antipsychotics, as well as a patient's prior or present experience with antipsychotic adverse events (AEs), were the primary factors that contributed to nonadherence. Patients on antipsychotic medication have to be given routine follow-up care that entails monitoring for adverse effects and, if necessary, appropriate therapies. This is due to the frequency with which such effects occur.

The results of not adhering

It has been shown that nonadherence to medication is linked to an increased chance of relapse, as well as rehospitalization, self-harm, and a worse quality of life. Schizophrenia is a continuous disorder that affects the majority of people; however, there is a tiny subset of individuals who suffer just a single episode of the illness and then go on to achieve a complete recovery. The incidence of recurrence is substantial, with a 5-year take research indicating a cumulative first rate of recidivism of 82% and a recurrent relapse rate of 78%. Both of these rates are higher than the overall survival rate. According to the findings of another research, 77% of symptoms returned within one year after medication was stopped, and more than 90% of symptoms returned within two years [59]–[61]. A prospective observational study that was carried out in the United States over the course of three years found connections between nonadherence to antipsychotic medication and a variety of unfavorable outcomes. These outcomes included increased visits to psychiatric hospitals and emergency departments, higher rates of substance abuse, and an elevated risk of violent behavior and arrests. It is important to stress that the great majority of people who have schizophrenia are not violent. In fact, people with schizophrenia are

more likely to be the victims of violent actions than the people who commit them.

Maintaining antipsychotic medication via supportive therapy does not prevent the danger of relapse, but it does considerably lessen the likelihood of it happening. Patients who were stable on antipsychotic treatment had a lower chance of relapse after one year, according to a meta-analysis of 65 studies, which indicated a relative risk of 0.40 with a 95% confidence interval ranging from 0.33 to 0.49. In addition, in comparison to patients who were given a placebo, these patients had a much higher rate of successful treatment and a lower risk of being admitted to the hospital. In addition, there was evidence to suggest that patients who were treated had an enhanced quality of life and had fewer instances of aggressive behavior. Although it is necessary to assess the benefits of pharmacotherapy against the adverse effects associated with it, the evidence clearly suggest that antipsychotic maintenance medication is beneficial to people who have schizophrenia.

Conclusions

Schizophrenia is a mental illness that causes individuals to exhibit negative symptoms such as delusions, hallucinations, disordered speech, and highly disorganized or delirious behavior, in addition to other negative symptoms and significant cognitive impairment. Patients are at risk for psychotic and its symptoms and effects due to a mix of both genetic and environmental variables. The precise etiology and mechanism of the condition have not yet been fully explained. Multiple comorbidities are linked to schizophrenia, which makes it more difficult to provide patients with the best possible care and may also restrict the range of possible good outcomes. In furthermore, adherence to the antipsychotic therapy that is advised for the illness is often inadequate and is impacted by a wide variety of risk factors with nonadherence that are connected to the patient, the environment, the therapist, and the treatment. Because there are so many potential obstacles to patient management, the data surrounding the guiding principles in schizophrenia management need to continue to evolve. This will allow for the provision of additional information and treatment options to patients as well as clinicians, with the potential to improve patient outcomes and quality of life for those who are afflicted with this widespread and serious mental health condition.

[1] A. T. Beck, R. Himelstein, and P. M. Grant, “In and out of schizophrenia: Activation and deactivation of the negative and positive schemas,” *Schizophr. Res.*, vol. 203, pp. 55–61, Jan. 2019.
[2] McGlashan, Walsh, and Woods, “Structured interview for psychosis-risk syndromes,” *New Haven, CT*, 2001.
[3] S. P. Stefanatou Pentagiotissa, G. K. George Konstantakopoulos, E. G. Eleni Giannouli, S. V. Silia Vitoratou, and V. M. Venetsanos Mavreas, “The relationship between patients’ needs and psychopathology in schizophrenia: Do patients and therapists agree?,” *Eur. Psychiatry*, vol. 30, p. 1376, Mar. 2015.
[4] Skodol, Bender, Morey, and Clark, “Personality disorder types proposed for DSM-5,” *Personal. Disord.*, 2011.
[5] B. Bach, M. Sellbom, S. Bo, and E. Simonsen, “Utility of DSM-5 section III personality traits in differentiating borderline personality disorder from comparison groups,” *Eur. Psychiatry*, vol. 37, pp. 22–27, Sep. 2016.
[6] M. Davidson, A. Reichenberg, J. Rabinowitz, M. Weiser, Z. Kaplan, and M. Mark, “Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents,” *Am. J. Psychiatry*, vol. 156, no. 9, pp. 1328–1335, Sep. 1999.
[7] P. Milev, B.-C. Ho, S. Arndt, and N. C. Andreasen, “Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up,” *Am. J. Psychiatry*, vol. 162, no. 3, pp. 495–506, Mar. 2005.
[8] G. Konstantakopoulos, N. Ioannidi, C. Psarros, P. Patrikelis, P. Stefanatou, and E. Kravariti, “The impact of neurocognition on mentalizing in euthymic bipolar disorder versus schizophrenia,” *Cogn. Neuropsychiatry*, vol. 25, no. 6, pp. 405–420, Nov. 2020.
[9] B. C. Ho, P. Nopoulos, M. Flaum, S. Arndt, and N. C. Andreasen, “Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life,” *Am. J. Psychiatry*, vol. 155, no. 9, pp. 1196–1201, Sep. 1998.
[10] E. K. Spencer and M. Campbell, “Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy,” *Schizophr. Bull.*, vol. 20, no. 4, pp. 713–725, 1994.
[11] M. Lahti *et al.*, “Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia,” *Psychol. Med.*, vol. 42, no. 11, pp. 2275–2285, Nov. 2012.
[12] J. N. Wilkins, “Pharmacotherapy of schizophrenia patients with comorbid substance abuse,” *Schizophr. Bull.*, vol. 23, no. 2, pp. 215–228, 1997.
[13] E. Granholm *et al.*, “A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia,” *Am. J. Psychiatry*, vol. 162, no. 3, pp. 520–529, Mar. 2005.
[14] P. Stefanatou, C.-S. Karatosidi, E. Tsompanaki, E. Kattoulas, N. C. Stefanis, and N. Smyrnis, “Premorbid adjustment predictors of cognitive dysfunction in schizophrenia,” *Psychiatry Res.*, vol. 267, pp. 249–255, Sep. 2018.
[15] M. J. Millan *et al.*, “Altering the course of schizophrenia: progress and perspectives,” *Nat. Rev. Drug Discov.*, vol. 15, no. 7, pp. 485–515, Jul. 2016.
[16] A. Jablensky *et al.*, “Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study,” *Psychol. Med. Monogr. Suppl.*, vol. 20, pp. 1–97, 1992.
[17] M. Rutter, “Childhood schizophrenia reconsidered,” *J. Autism Child. Schizophr.*, vol. 2, no. 4, pp. 315–337, Oct. 1972.
[18] W. Health Organization, “Report of the international pilot study of schizophrenia,” 1973. [Online].
[19] R. Tandon, M. S. Keshavan, and H. A. Nasrallah, “Schizophrenia, ‘Just the Facts’ What we know in 2008. 2. Epidemiology and etiology,” *Schizophr. Res.*, vol. 102, no. 1, pp. 1–18, Jul. 2008.
[20] L. W. Goldstone, “Unmet medical needs and other challenges in the treatment of patients with schizophrenia,” *Am. J. Manag. Care*, vol. 26, no. 3 Suppl, pp. S48–S54, Mar. 2020.

[21] J. McGrath, S. Saha, D. Chant, and J. Welham, “Schizophrenia: a concise overview of incidence, prevalence, and mortality,” *Epidemiol. Rev.*, vol. 30, pp. 67–76, May 2008.
[22] L. E. DeLisi, L. R. Goldin, M. E. Maxwell, D. M. Kazuba, and E. S. Gershon, “Clinical features of illness in siblings with schizophrenia or schizoaffective disorder,” *Arch. Gen. Psychiatry*, vol. 44, no. 10, pp. 891–896, Oct. 1987.
[23] L. E. DeLisi, “The significance of age of onset for schizophrenia,” *Schizophr. Bull.*, vol. 18, no. 2, pp. 209–215, 1992.
[24] E. Aylward, E. Walker, and B. Bettes, “Intelligence in schizophrenia: meta-analysis of the research,” *Schizophr. Bull.*, vol. 10, no. 3, pp. 430–459, 1984.
[25] S. Dimitrakopoulos, A. Hatzimanolis, P. Stefanatou, L.-A. Xenaki, and N. Stefanis, “S125. The role of dup, DUI and polygenic score for schizophrenia on cognition in Athens fep study sample,” *Schizophr. Bull.*, vol. 46, no. Supplement_1, pp. S82–S83, May 2020.
[26] T. D. Cannon *et al.*, “Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls,” *Arch. Gen. Psychiatry*, vol. 59, no. 1, pp. 35–41, Jan. 2002.
[27] P. C. Fletcher and C. D. Frith, “Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia,” *Nat. Rev. Neurosci.*, vol. 10, no. 1, pp. 48–58, Jan. 2009.
[28] M. van den Buuse, “Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects,” *Schizophr. Bull.*, vol. 36, no. 2, pp. 246–270, Mar. 2010.
[29] L. A. Xenaki, C. T. Kollias, and P. Stefanatou, “Organization framework and preliminary findings from the Athens First-Episode Psychosis Research Study,” *Early Interv. Psychiatry*, 2020.
[30] S. H. Schultz, S. W. North, and C. G. Shields, “Schizophrenia: a review,” *Am. Fam. Physician*, vol. 75, no. 12, pp. 1821–1829, Jun. 2007.
[31] P. Stefanatou and E. Giannouli, “EPA-1030–The greek version of the camberwell assessment of need: psychometric properties and associations with quality of life and social disability in …,” *European*, 2014.
[32] N. C. Andreasen and S. Olsen, “Negative v positive schizophrenia. Definition and validation,” *Arch. Gen. Psychiatry*, vol. 39, no. 7, pp. 789–794, Jul. 1982.
[33] S. R. Kay and S. Sevy, “Pyramidical model of schizophrenia,” *Schizophr. Bull.*, vol. 16, no. 3, pp. 537–545, 1990.
[34] P. F. Liddle, “The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy,” *Br. J. Psychiatry*, vol. 151, pp. 145–151, Aug. 1987.
[35] B. Angrist, J. Rotrosen, and S. Gershon, “Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia,” *Psychopharmacology* , vol. 72, no. 1, pp. 17–19, 1980.
[36] P. F. Liddle, K. J. Friston, C. D. Frith, S. R. Hirsch, T. Jones, and R. S. Frackowiak, “Patterns of cerebral blood flow in schizophrenia,” *Br. J. Psychiatry*, vol. 160, pp. 179–186, Feb. 1992.
[37] L.-A. Xenaki *et al.*, “Organization framework and preliminary findings from the Athens First-Episode Psychosis Research Study,” *Early Interv. Psychiatry*, vol. 14, no. 3, pp. 343–355, Jun. 2020.
[38] C. A. Ross, G. Anderson, and P. Clark, “Childhood Abuse andthe Positive Symptoms of Schizophrenia,” *PS* , vol. 45, no. 5, pp. 489–491, May 1994.
[39] J. B. Lohr and K. Flynn, “Smoking and schizophrenia,” *Schizophr. Res.*, vol. 8, no. 2, pp. 93–102, Dec. 1992.
[40] M. Šagud, A. Mihaljević-Peleš, and D. Mück-Šeler, “Smoking and schizophrenia,” *Psychiatria*, 2009.
[41] J. de Leon, M. Dadvand, C. Canuso, A. O. White, J. K. Stanilla, and G. M. Simpson, “Schizophrenia and smoking: An epidemiological survey in a state hospital,” *Am. J. Psychiatry*, vol. 152, no. 3, pp. 453–455, Mar. 1995.

[42] J. de Leon, “Smoking and vulnerability for schizophrenia,” *Schizophr. Bull.*, vol. 22, no. 3, pp. 405–409, 1996.
[43] P. Stefanatou, E. Giannouli, and P. Tsellos, “Metacognitive factors in a sample of Greek alcohol dependent patients,” *European*, 2016.
[44] J. Addington, N. el-Guebaly, W. Campbell, D. C. Hodgins, and D. Addington, “Smoking cessation treatment for patients with schizophrenia,” *Am. J. Psychiatry*, vol. 155, no. 7, pp. 974–976, Jul. 1998.
[45] S. R. Hirsch and A. G. Jolley, “The dysphoric syndrome in schizophrenia and its implications for relapse,” *Br. J. Psychiatry Suppl.*, no. 5, pp. 46–50, Jul. 1989.
[46] S. R. Hirsch *et al.*, “Dysphoric and depressive symptoms in chronic schizophrenia,” *Schizophr. Res.*, vol. 2, no. 3, pp. 259–264, May 1989.
[47] R. M. Norman and A. K. Malla, “Dysphoric mood and symptomatology in schizophrenia,” *Psychol. Med.*, vol. 21, no. 4, pp. 897–903, Nov. 1991.
[48] A. Malla and J. Payne, “First-episode psychosis: psychopathology, quality of life, and functional outcome,” *Schizophr. Bull.*, vol. 31, no. 3, pp. 650–671, Jul. 2005.
[49] K. Kollias *et al.*, “The development of the Early Intervention in Psychosis (EIP) outpatient unit of Eginition University Hospital into an EIP Network,” *Psychiatrike*, vol. 31, no. 2, pp. 177–182, Apr. 2020.
[50] D. Blumer, G. Montouris, and K. Davies, “The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy,” *Epilepsy Behav.*, vol. 5, no. 6, pp. 826–840, Dec. 2004.
[51] S. Souraya, C. Hanlon, and L. Asher, “Involvement of people with schizophrenia in decision-making in rural Ethiopia: a qualitative study,” *Global. Health*, vol. 14, no. 1, p. 85, Aug. 2018.
[52] C. J. Asher and L. Gask, “Reasons for illicit drug use in people with schizophrenia: Qualitative study,” *BMC Psychiatry*, vol. 10, p. 94, Nov. 2010.
[53] A. Watkins, A. John, C. Bradshaw, J. Jones, and M. Jones, “Schizophrenia in high risk opioid users: A short communication on an autopsy study,” *Psychiatry Res.*, vol. 276, pp. 112–114, Jun. 2019.
[54] F. de S. Ramiro, R. da C. Padovani, and A. M. Tucci, “Crack consumption from the perspective of gender and vulnerability: a review on the phenomenon,” *Saúde debate*, vol. 38, no. 101, pp. 379–392, 2014.
[55] A. Hatzimanolis *et al.*, “Familial and socioeconomic contributions to premorbid functioning in psychosis: Impact on age at onset and treatment response,” *Eur. Psychiatry*, vol. 63, no. 1, p. e44, Apr. 2020.
[56] N. C. Andreasen and W. T. Carpenter Jr, “Diagnosis and classification of schizophrenia,” *Schizophr. Bull.*, vol. 19, no. 2, pp. 199–214, 1993.
[57] N. C. Andreasen, “Symptoms, signs, and diagnosis of schizophrenia,” *Lancet*, vol. 346, no. 8973, pp. 477–481, Aug. 1995.
[58] N. C. Andreasen, S. Arndt, R. Alliger, D. Miller, and M. Flaum, “Symptoms of schizophrenia. Methods, meanings, and mechanisms,” *Arch. Gen. Psychiatry*, vol. 52, no. 5, pp. 341–351, May 1995.
[59] S. Kapur, “Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia,” *Am. J. Psychiatry*, vol. 160, no. 1, pp. 13–23, Jan. 2003.
[60] P. El-Mallakh and J. Findlay, “Strategies to improve medication adherence in patients with schizophrenia: the role of support services,” *Neuropsychiatr. Dis. Treat.*, vol. 11, pp. 1077–1090, Apr. 2015.
[61] S. R. López, M. del C. Lara, A. Kopelowicz, S. Solano, H. Foncerrada, and A. Aguilera, “La CLAve to increase psychosis literacy of Spanish-speaking community residents and family caregivers,” *J. Consult. Clin. Psychol.*, vol. 77, no. 4, pp. 763–774, Aug. 2009.